Cargando…

Histopathology-validated lesion detection rates of clinically significant prostate cancer with mpMRI, [(68)Ga]PSMA-11-PET and [(11)C]Acetate-PET

OBJECTIVE: PET/CT and multiparametric MRI (mpMRI) are important diagnostic tools in clinically significant prostate cancer (csPC). The aim of this study was to compare csPC detection rates with [(68)Ga]PSMA-11-PET (PSMA)-PET, [(11)C]Acetate (ACE)-PET, and mpMRI with histopathology as reference, to i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sandgren, Kristina, Strandberg, Sara N., Jonsson, Joakim H., Grefve, Josefine, Keeratijarut Lindberg, Angsana, Nilsson, Erik, Bergh, Anders, Söderkvist, Karin, Thellenberg Karlsson, Camilla, Friedrich, Bengt, Widmark, Anders, Blomqvist, Lennart, Berg Loegager, Vibeke, Axelsson, Jan, Ögren, Mattias, Ögren, Margareta, Nyholm, Tufve, Riklund, Katrine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566593/ https://www.ncbi.nlm.nih.gov/pubmed/37615497 http://dx.doi.org/10.1097/MNM.0000000000001743

Ejemplares similares

The grade of individual prostate cancer lesions predicted by magnetic resonance imaging and positron emission tomography
por: Nilsson, Erik, et al.
Publicado: (2023)

Registration of histopathology to magnetic resonance imaging of prostate cancer
por: Sandgren, Kristina, et al.
Publicado: (2021)

Radiation dosimetry of [(68)Ga]PSMA-11 in low-risk prostate cancer patients
por: Sandgren, Kristina, et al.
Publicado: (2019)

(11)C-acetate PET/CT in pre-therapeutic lymph node staging in high-risk prostate cancer patients and its influence on disease management - a retrospective study
por: Strandberg, Sara, et al.
Publicado: (2014)

Comparison of (68)Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer
por: Zhang, Qing, et al.
Publicado: (2017)

Hyaluronic acid spacer in prostate cancer radiotherapy: dosimetric effects, spacer stability and long-term toxicity and PRO in a phase II study
por: Björeland, Ulrika, et al.
Publicado: (2023)

Improved PET/MRI attenuation correction in the pelvic region using a statistical decomposition method on T2-weighted images
por: Wallstén, Elin, et al.
Publicado: (2020)

Optimization of PET reconstruction algorithm, SUV thresholding algorithm and PET acquisition time in clinical (11)C-acetate PET/CT
por: Strandberg, Sara, et al.
Publicado: (2018)

Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI
por: Laudicella, Riccardo, et al.
Publicado: (2022)

False-positive mpMRI and true-negative (68)Ga-PSMA PET/CT xanthogranulomatous prostatitis: a case report
por: Tang, Yongxiang, et al.
Publicado: (2022)

Correlation between genomic index lesions and mpMRI and (68)Ga-PSMA-PET/CT imaging features in primary prostate cancer
por: Kesch, Claudia, et al.
Publicado: (2018)

Incremental Impact of [(68) Ga]Ga-PSMA-11 PET/CT in Primary N and M Staging of Prostate Cancer Prior to Curative-Intent Surgery: a Prospective Clinical Trial in Comparison with mpMRI
por: Szigeti, Florian, et al.
Publicado: (2021)

Impact of neoadjuvant androgen deprivation therapy on magnetic resonance imaging features in prostate cancer before radiotherapy
por: Björeland, Ulrika, et al.
Publicado: (2021)

Targeted 11C–choline PET-CT/TRUS software fusion-guided prostate biopsy in men with persistently elevated PSA and negative mpMRI after previous negative biopsy
por: Lazzeri, Massimo, et al.
Publicado: (2017)

Role of mpMRI of the prostate in screening for prostate cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2017)

Intraindividual comparison between (68)Ga-PSMA-PET/CT and mpMRI for intraprostatic tumor delineation in patients with primary prostate cancer: a retrospective analysis in 101 patients
por: Spohn, Simon, et al.
Publicado: (2020)

Comparison of (68)Ga-PSMA-617 PET/CT with mpMRI for the detection of PCa in patients with a PSA level of 4–20 ng/ml before the initial biopsy
por: Li, Yu, et al.
Publicado: (2020)

Case report: PSMA PET/CT addresses the correct diagnosis in a patient with metastatic prostate cancer despite negative core biopsies and mpMRI. A diagnostic challenge
por: Vetrone, Luigia, et al.
Publicado: (2023)

Mischievous malakoplakia: A potential pitfall of mpMRI of the prostate?
por: Rezaee, Michael E., et al.
Publicado: (2020)

The combined value of mpUS and mpMRI-TRUS fusion for the diagnosis of clinically significant prostate cancer
por: Zhang, Xin, et al.
Publicado: (2022)

PET/MRI and PET/CT hybrid imaging of rectal cancer – description and initial observations from the RECTOPET (REctal Cancer trial on PET/MRI/CT) study
por: Rutegård, Miriam K., et al.
Publicado: (2019)

The rationale for MR-only treatment planning for external radiotherapy
por: Jonsson, Joakim, et al.
Publicado: (2019)

Pearls and pitfalls in diagnosing prostate cancer using multiparametric MRI (mpMRI)
por: Joshi, JJ, et al.
Publicado: (2015)

Optimising preoperative risk stratification tools for prostate cancer using mpMRI
por: Reisæter, Lars A. R., et al.
Publicado: (2017)

Differential diagnosis of uncommon prostate diseases: combining mpMRI and clinical information
por: Han, Chao, et al.
Publicado: (2021)

Comparison of (68)Ga-PSMA-11 PET/CT with (11)C-acetate PET/CT in re-staging of prostate cancer relapse
por: Regula, Naresh, et al.
Publicado: (2020)

(68)Ga-PSMA-PET/CT in addition to mpMRI in men undergoing biopsy during active surveillance for low- to intermediate-risk prostate cancer: study protocol for a prospective cross-sectional study
por: Gondoputro, William, et al.
Publicado: (2023)

Microvascular proliferation is associated with high tumour blood flow by mpMRI and disease progression in primary prostate cancer
por: Børretzen, Astrid, et al.
Publicado: (2023)

Dopamine transporter imaging with [(18)F]FE-PE2I PET and [(123)I]FP-CIT SPECT—a clinical comparison
por: Jakobson Mo, Susanna, et al.
Publicado: (2018)

Electrochemical [(11)C]CO(2) to [(11)C]CO conversion for PET imaging
por: Anders, David A., et al.
Publicado: (2017)

Investigation of the halo-artifact in (68)Ga-PSMA-11-PET/MRI
por: Heußer, Thorsten, et al.
Publicado: (2017)

Applications of Artificial Intelligence to Prostate Multiparametric MRI (mpMRI): Current and Emerging Trends
por: Bardis, Michelle D., et al.
Publicado: (2020)

bpMRI and mpMRI for detecting prostate cancer: A retrospective cohort study
por: Pan, Yongsheng, et al.
Publicado: (2023)

AI-predicted mpMRI image features for the prediction of clinically significant prostate cancer
por: Li, Song, et al.
Publicado: (2023)

Haralick texture features from apparent diffusion coefficient (ADC) MRI images depend on imaging and pre-processing parameters
por: Brynolfsson, Patrik, et al.
Publicado: (2017)

Hybrid imaging with [(68)Ga]PSMA-11 PET-CT and PET-MRI in biochemically recurrent prostate cancer
por: Glemser, P. A., et al.
Publicado: (2022)

(68)Ga-PSMA-11 PET/CT versus (68)Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis
por: Huang, Ruizhe, et al.
Publicado: (2023)

Ga-68-PSMA PET/CT ? or PET/MRI ?, Mp-MRI ? in diagnosis and radiotherapy planning in a patient with prostate cancer
por: Cihan, Yasemin Benderli
Publicado: (2020)

Rectal cancer: a methodological approach to matching PET/MRI to histopathology
por: Rutegård, Miriam K., et al.
Publicado: (2020)

Analysis of the cause of missed diagnosis in mpMRI/TRUS fusion-guided targeted prostate biopsy
por: Zhang, Fan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tp94pfa51b1i3rm9obkt5nvnlv